thiazolyl blue and dactolisib
thiazolyl blue has been researched along with dactolisib in 2 studies
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S | 1 |
Fu, W; Hu, L; Zhu, W | 1 |
Other Studies
2 other study(ies) available for thiazolyl blue and dactolisib
Article | Year |
---|---|
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Flow Cytometry; Humans; Imidazoles; Male; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Quinolines; Radiation Tolerance; Radiation, Ionizing; Radiopharmaceuticals; Receptors, Androgen; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases | 2013 |